Literature DB >> 31606435

Lung function decline in former smokers and low-intensity current smokers: a secondary data analysis of the NHLBI Pooled Cohorts Study.

Elizabeth C Oelsner1, Pallavi P Balte2, Surya P Bhatt3, Patricia A Cassano4, David Couper5, Aaron R Folsom6, Neal D Freedman7, David R Jacobs6, Ravi Kalhan8, Amanda R Mathew9, Richard A Kronmal10, Laura R Loehr5, Stephanie J London11, Anne B Newman12, George T O'Connor13, Joseph E Schwartz2, Lewis J Smith8, Wendy B White14, Sachin Yende12.   

Abstract

BACKGROUND: Former smokers now outnumber current smokers in many developed countries, and current smokers are smoking fewer cigarettes per day. Some data suggest that lung function decline normalises with smoking cessation; however, mechanistic studies suggest that lung function decline could continue. We hypothesised that former smokers and low-intensity current smokers have accelerated lung function decline compared with never-smokers, including among those without prevalent lung disease.
METHODS: We used data on six US population-based cohorts included in the NHLBI Pooled Cohort Study. We restricted the sample to participants with valid spirometry at two or more exams. Two cohorts recruited younger adults (≥17 years), two recruited middle-aged and older adults (≥45 years), and two recruited only elderly adults (≥65 years) with examinations done between 1983 and 2014. FEV1 decline in sustained former smokers and current smokers was compared to that of never-smokers by use of mixed models adjusted for sociodemographic and anthropometric factors. Differential FEV1 decline was also evaluated according to duration of smoking cessation and cumulative (number of pack-years) and current (number of cigarettes per day) cigarette consumption.
FINDINGS: 25 352 participants (ages 17-93 years) completed 70 228 valid spirometry exams. Over a median follow-up of 7 years (IQR 3-20), FEV1 decline at the median age (57 years) was 31·01 mL per year (95% CI 30·66-31·37) in sustained never-smokers, 34·97 mL per year (34·36-35·57) in former smokers, and 39·92 mL per year (38·92-40·92) in current smokers. With adjustment, former smokers showed an accelerated FEV1 decline of 1·82 mL per year (95% CI 1·24-2·40) compared to never-smokers, which was approximately 20% of the effect estimate for current smokers (9·21 mL per year; 95% CI 8·35-10·08). Compared to never-smokers, accelerated FEV1 decline was observed in former smokers for decades after smoking cessation and in current smokers with low cumulative cigarette consumption (<10 pack-years). With respect to current cigarette consumption, the effect estimate for FEV1 decline in current smokers consuming less than five cigarettes per day (7·65 mL per year; 95% CI 6·21-9·09) was 68% of that in current smokers consuming 30 or more cigarettes per day (11·24 mL per year; 9·86-12·62), and around five times greater than in former smokers (1·57 mL per year; 1·00-2·14). Among participants without prevalent lung disease, associations were attenuated but were consistent with the main results.
INTERPRETATION: Former smokers and low-intensity current smokers have accelerated lung function decline compared with never-smokers. These results suggest that all levels of smoking exposure are likely to be associated with lasting and progressive lung damage. FUNDING: National Institutes of Health, National Heart Lung and Blood Institute, and US Environmental Protection Agency.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31606435      PMCID: PMC7261004          DOI: 10.1016/S2213-2600(19)30276-0

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN: 2213-2600            Impact factor:   102.642


  51 in total

1.  Standardisation of spirometry.

Authors:  M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger
Journal:  Eur Respir J       Date:  2005-08       Impact factor: 16.671

2.  Small airway function improvement after smoking cessation in smokers without airway obstruction.

Authors:  Sylvia Verbanck; Daniël Schuermans; Manuel Paiva; Marc Meysman; Walter Vincken
Journal:  Am J Respir Crit Care Med       Date:  2006-06-23       Impact factor: 21.405

Review 3.  Longitudinal studies of active and passive smoking.

Authors:  J M Samet; P Lange
Journal:  Am J Respir Crit Care Med       Date:  1996-12       Impact factor: 21.405

4.  Adolescents' perceptions of light and intermittent smoking in the United States.

Authors:  Stephen M Amrock; Michael Weitzman
Journal:  Pediatrics       Date:  2015-01-12       Impact factor: 7.124

5.  Cigarette smoking and variations in systemic immune and inflammation markers.

Authors:  Meredith S Shiels; Hormuzd A Katki; Neal D Freedman; Mark P Purdue; Nicolas Wentzensen; Britton Trabert; Cari M Kitahara; Michael Furr; Yan Li; Troy J Kemp; James J Goedert; Cindy M Chang; Eric A Engels; Neil E Caporaso; Ligia A Pinto; Allan Hildesheim; Anil K Chaturvedi
Journal:  J Natl Cancer Inst       Date:  2014-10-01       Impact factor: 13.506

6.  Harmonization of Respiratory Data From 9 US Population-Based Cohorts: The NHLBI Pooled Cohorts Study.

Authors:  Elizabeth C Oelsner; Pallavi P Balte; Patricia A Cassano; David Couper; Paul L Enright; Aaron R Folsom; John Hankinson; David R Jacobs; Ravi Kalhan; Robert Kaplan; Richard Kronmal; Leslie Lange; Laura R Loehr; Stephanie J London; Ana Navas Acien; Anne B Newman; George T O'Connor; Joseph E Schwartz; Lewis J Smith; Fawn Yeh; Yiyi Zhang; Andrew E Moran; Stanford Mwasongwe; Wendy B White; Sachin Yende; R Graham Barr
Journal:  Am J Epidemiol       Date:  2018-11-01       Impact factor: 4.897

7.  Determinants of Light and Intermittent Smoking in the United States: Results from Three Pooled National Health Surveys.

Authors:  Carolyn M Reyes-Guzman; Ruth M Pfeiffer; Jay Lubin; Neal D Freedman; Sean D Cleary; Paul H Levine; Neil E Caporaso
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-10-19       Impact factor: 4.254

8.  Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group.

Authors:  J Vestbo; E Prescott; P Lange
Journal:  Am J Respir Crit Care Med       Date:  1996-05       Impact factor: 21.405

9.  Comparison of Puff Volume With Cigarettes per Day in Predicting Nicotine Uptake Among Daily Smokers.

Authors:  Nicolle M Krebs; Allshine Chen; Junjia Zhu; Dongxiao Sun; Jason Liao; Andrea L Stennett; Joshua E Muscat
Journal:  Am J Epidemiol       Date:  2016-06-16       Impact factor: 4.897

10.  Current Cigarette Smoking Among Adults - United States, 2016.

Authors:  Ahmed Jamal; Elyse Phillips; Andrea S Gentzke; David M Homa; Stephen D Babb; Brian A King; Linda J Neff
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-01-19       Impact factor: 17.586

View more
  25 in total

1.  Development of a Blood-based Transcriptional Risk Score for Chronic Obstructive Pulmonary Disease.

Authors:  Matthew Moll; Adel Boueiz; Auyon J Ghosh; Aabida Saferali; Sool Lee; Zhonghui Xu; Jeong H Yun; Brian D Hobbs; Craig P Hersh; Don D Sin; Ruth Tal-Singer; Edwin K Silverman; Michael H Cho; Peter J Castaldi
Journal:  Am J Respir Crit Care Med       Date:  2022-01-15       Impact factor: 21.405

2.  Prevalence and Population Attributable Risk for Early Chronic Obstructive Pulmonary Disease in U.S. Hispanic/Latino Individuals.

Authors:  Fariha Khalid; Wei Wang; David Mannino; Alejandro A Diaz
Journal:  Ann Am Thorac Soc       Date:  2022-03

3.  Association of Nonobstructive Chronic Bronchitis With Respiratory Health Outcomes in Adults.

Authors:  Pallavi P Balte; Paulo H M Chaves; David J Couper; Paul Enright; David R Jacobs; Ravi Kalhan; Richard A Kronmal; Laura R Loehr; Stephanie J London; Anne B Newman; George T O'Connor; Joseph E Schwartz; Benjamin M Smith; Lewis J Smith; Wendy B White; Sachin Yende; Elizabeth C Oelsner
Journal:  JAMA Intern Med       Date:  2020-05-01       Impact factor: 21.873

4.  Ticagrelor reduces ischaemic risk in patients with CAD and diabetes.

Authors:  Karina Huynh
Journal:  Nat Rev Cardiol       Date:  2019-11       Impact factor: 32.419

5.  Bronchopulmonary dysplasia as a determinant of respiratory outcomes in adult life.

Authors:  Joseph M Collaco; Sharon A McGrath-Morrow
Journal:  Pediatr Pulmonol       Date:  2021-03-17

Review 6.  Cardiovascular risk factors, cardiovascular disease, and COVID-19: an umbrella review of systematic reviews.

Authors:  Stephanie L Harrison; Benjamin J R Buckley; José Miguel Rivera-Caravaca; Juqian Zhang; Gregory Y H Lip
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2021-07-21

Review 7.  Impaired Respiratory Health and Life Course Transitions From Health to Chronic Lung Disease.

Authors:  Gabrielle Y Liu; Ravi Kalhan
Journal:  Chest       Date:  2021-04-15       Impact factor: 10.262

8.  Effect of lung function disorders and physical activity on smoking and non-smoking students.

Authors:  Amelia Lorensia; Cynthia Marisca Muntu; Rivan Virlando Suryadinata; Roslin Septiani
Journal:  J Prev Med Hyg       Date:  2021-04-29

9.  Mendelian randomization analysis of arsenic metabolism and pulmonary function within the Hispanic Community Health Study/Study of Latinos.

Authors:  Molly Scannell Bryan; Tamar Sofer; Majid Afshar; Yasmin Mossavar-Rahmani; H Dean Hosgood; Naresh M Punjabi; Donglin Zeng; Martha L Daviglus; Maria Argos
Journal:  Sci Rep       Date:  2021-06-29       Impact factor: 4.379

10.  Does Regular Physical Activity Mitigate the Age-Associated Decline in Pulmonary Function?

Authors:  Johannes Burtscher; Grégoire P Millet; Hannes Gatterer; Karin Vonbank; Martin Burtscher
Journal:  Sports Med       Date:  2022-02-03       Impact factor: 11.928

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.